Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 24, 2023

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Crohns Disease
Interventions
DRUG

Afimkibart

Afimkibart will be administered during the Induction, Maintenance and OLE period.

Trial Locations (11)

8800

AZ Delta, Roeselare

34741

I.H.S Health Northwell Health, Kissimmee

36305

Digestive Health Specialists, Dothan

44093

CHU de Nantes, Nantes

48047

Clinical Research Institute of Michigan, Chesterfield

54500

CHRU de Nancy Brabois, Vandœuvre-lès-Nancy

92200

Institut des MICI, Clinique Ambroise Paré, Neuilly-sur-Seine

06518

Medical Research Center of Connecticut, LLC, Hamden

02115

Brigham and Women's Hospital, Boston

71-434

Twoja Przychodnia-Szczecinskie Centrum Medyczne, Szczecin

00-728

WIP Warsaw IBD Point Profesor Kierkus, Warsaw

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY